

BACKGROUND

- Myelofibrosis (MF) is a heterogeneous, progressive, and fatal disease.¹ Underlying biological hallmarks include aberrant blood and bone marrow differentiation, cytokine production and inflammation, bone marrow fibrosis, and extramedullary hematopoiesis.^{1,2}
- An urgent need persists for therapies, beyond Janus kinase inhibitors (JAKi), with rapid, effective, and durable responses that address underlying drivers of MF, due to limited responses as well as the lack of evidence of disease modification, treatments for patients with cytopenic MF, and improved outcomes.^{2,3}
- Selinexor, an oral exportin 1 (XPO1) inhibitor with pro-apoptotic and anti-inflammatory properties that may impact both Janus kinase (JAK) and non-JAK pathways, is undergoing investigation for treatment of MF.^{4,5}

STUDY DESIGN

- Based on the Phase 1 results, the combination of selinexor and ruxolitinib is being evaluated in a double-blind, randomized, placebo-controlled Phase 3 study.^{6,7}
- 350 JAKi-naïve patients with MF are expected to be enrolled in a 2:1 ratio to receive selinexor + ruxolitinib or placebo + ruxolitinib.^{6,7}

SELECT STUDY OBJECTIVES

- To evaluate the efficacy (SVR35 and absolute TSS at Week 24) of selinexor + ruxolitinib vs placebo + ruxolitinib in JAKi-naïve patients with MF.^{6,7}
- To evaluate safety of selinexor + ruxolitinib compared to placebo + ruxolitinib in patients with MF.^{5,6}

CONTACT


clinicaltrials@karyopharm.com



A Global, Multicenter, Double-blind, Phase 1/3 Study of Selinexor in Combination with Ruxolitinib in JAKi Treatment-naïve Patients with Myelofibrosis (NCT04562389)

PHASE 3 TRIAL DESIGN

Study Status: Actively Recruiting



Randomization stratified by:

- Dynamic International Prognostic Scoring System (DIPSS) risk category intermediate -1 vs. intermediate -2 or high-risk
- Spleen volume < 1800 cm³ vs. ≥ 1800 cm³ by MRI/CT scan
- Baseline platelet counts 100–200 × 10⁹/L vs. > 200 × 10⁹/L

SELECT INCLUSION CRITERIA^{6,7}

- ≥ 18 years of age
- A diagnosis of primary MF or post-ET or post-(PV) MF
- Measurable splenomegaly as demonstrated by spleen volume of ≥ 450 cm³ by MRI or CT scan
- DIPSS risk category of intermediate-1, or intermediate-2, or high-risk
- Active symptoms of MF as determined by presence of at least 2 symptoms with an average score ≥ 5 or an average total score of ≥ 12 using the MFSAF v4.0
- Participant currently not eligible for stem cell transplantation
- ECOG PS ≤ 2
- Platelet count ≥ 100 × 10⁹/L
- CrCl > 15 mL/min

SELECT EXCLUSION CRITERIA^{6,7}

- More than 10% blasts in peripheral blood or bone marrow (accelerated or blast phase)
- Previous treatment with JAKi
- Previous treatment with selinexor or other XPO1 inhibitors
- Impairment of GI function or GI disease that could significantly alter the absorption of selinexor

BID, twice a day; CrCl, creatinine clearance; CT, computer topography; DIPSS, Dynamic International Prognostic Scoring System; ECOG PS, Eastern Cooperative Oncology Group Performance Status; GI, gastrointestinal; JAK, Janus kinase; JAKi, Janus kinase inhibitor; MF, myelofibrosis; MFSAF, Myelofibrosis Symptom Assessment Form; MRI, magnetic resonance imaging; PV, polycythemia vera; QW, once a week; SVR35, spleen volume reduction ≥ 35%; TSS, total symptom score; XPO1, exportin-1.

1. Tefferi A. *Am J Hematol*. 2023;98(5):801–21. 2. O'Sullivan JM, Harrison CN. *Clin Adv Hematol Oncol*. 2018;16(2):121–31. 3. Levavi H, et al. *Clin Adv Hematol Oncol*. 2022;20(7):456–67. 4. Kashyap T, et al. *Oncotarget*. 2016;7(48):78883–95. 5. Maloof M, et al. Poster presented at: the 15th International Congress for Myeloproliferative Neoplasms (MPN); November 2–3, 2023; Brooklyn, NY. 6. Karyopharm Therapeutics Inc. Data on File. 7. ClinicalTrials.gov. NCT04562389. <https://clinicaltrials.gov/ct2/show/NCT04562389>. Accessed February 25, 2025.



Scan here for
more information
on ClinicalTrials.gov